The company has revealed it added approximately $6m to a series A round co-led by AbbVie Ventures last year, bringing its total size to about $59m.
US-based immunotherapy developer Carisma Therapeutics has increased a series A round backed by pharmaceutical firms AbbVie and Merck & Co to approximately $59m, Technical.ly Philly has reported.
Carisma had achieved a first $53m close for the round in June 2018 which was co-led by AbbVie’s corporate venturing unit, AbbVie Ventures, and venture capital firm HealthCap, with participation from Merck & Co’s MRL Ventures Fund.
The company secured approximately $6m in an extension towards the end of 2018, according to…
